{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T23:46:12Z","timestamp":1775864772825,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kyowa Kirin Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Levodopa remains the most effective symptomatic treatment for Parkinson\u2019s disease (PD) more than 50\u00a0years after its clinical introduction. However, the onset of motor complications can limit pharmacological intervention with levodopa, which can be a challenge when treating PD patients. Clinical data suggest using the lowest possible levodopa dose to balance the risk\/benefit. Istradefylline, an adenosine A<jats:sub>2A<\/jats:sub>receptor antagonist indicated as an adjunctive treatment to levodopa-containing preparations in PD patients experiencing wearing off, is currently available in Japan and the US. Preclinical and preliminary clinical data suggested that adjunctive istradefylline may provide sustained antiparkinsonian benefits without a levodopa dose increase; however, available data on the impact of istradefylline on levodopa dose titration are limited. The ISTRA ADJUST PD study will evaluate the effect of adjunctive istradefylline on levodopa dosage titration in PD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This 37-week, multicenter, randomized, open-label, parallel-group controlled study in PD patients aged 30\u201384\u00a0years who are experiencing the wearing-off phenomenon despite receiving levodopa-containing medications\u2009\u2265\u20093 times daily (daily dose 300\u2013400\u00a0mg) began in February 2019 and will continue until February 2022. Enrollment is planned to attain 100 evaluable patients for the efficacy analyses. Patients will receive adjunctive istradefylline (20\u00a0mg\/day, increasing to 40\u00a0mg\/day) or the control in a 1:1 ratio, stratified by age, levodopa equivalent dose, and presence\/absence of dyskinesia. During the study, the levodopa dose will be increased according to symptom severity. The primary study endpoint is the comparison of the cumulative additional dose of levodopa-containing medications during the treatment period between the adjunctive istradefylline and control groups. Secondary endpoints include changes in efficacy rating scales and safety outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study aims to clarify whether adjunctive istradefylline can reduce the cumulative additional dose of levodopa-containing medications in PD patients experiencing the wearing-off phenomenon, and lower the risk of levodopa-associated complications. It is anticipated that data from ISTRA ADJUST PD will help inform future clinical decision-making for patients with PD in the real-world setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>Japan Registry of Clinical Trials,<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/jrct.niph.go.jp\/latest-detail\/jRCTs031180248\">jRCTs031180248<\/jats:ext-link>; registered 12 March 2019.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12883-022-02600-w","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T09:03:12Z","timestamp":1646298192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson\u2019s disease: study protocol for the ISTRA ADJUST PD randomized, controlled study"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6808-0444","authenticated-orcid":false,"given":"Taku","family":"Hatano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Kano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renpei","family":"Sengoku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asako","family":"Yoritaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoichi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihito","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morinobu","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho Kawabe","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroo","family":"Terashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetomo","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideto","family":"Joki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Ogaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiro","family":"Fukae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimasa","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naotake","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nagayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"issue":"6","key":"2600_CR1","first-page":"573","volume":"34","author":"L Cuenca","year":"2019","unstructured":"Cuenca L, Gil-Martinez AL, Cano-Fernandez L, Sanchez-Rodrigo C, Estrada C, Fernandez-Villalba E, et al. Parkinson\u2019s disease: a short story of 200 years. Histol Histopathol. 2019;34(6):573\u201391.","journal-title":"Histol Histopathol"},{"issue":"15","key":"2600_CR2","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1056\/NEJM199810083391506","volume":"339","author":"AE Lang","year":"1998","unstructured":"Lang AE, Lozano AM. Parkinson\u2019s disease First of two parts. N Engl J Med. 1998;339(15):1044\u201353.","journal-title":"N Engl J Med"},{"issue":"1","key":"2600_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ene.14108","volume":"27","author":"R Balestrino","year":"2020","unstructured":"Balestrino R, Schapira AHV. Parkinson disease. Eur J Neurol. 2020;27(1):27\u201342.","journal-title":"Eur J Neurol"},{"issue":"1","key":"2600_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/mds.26102","volume":"30","author":"S Fahn","year":"2015","unstructured":"Fahn S. The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord. 2015;30(1):4\u201318.","journal-title":"Mov Disord"},{"issue":"Suppl 2","key":"2600_CR5","doi-asserted-by":"publisher","first-page":"S249","DOI":"10.1007\/s00415-010-5741-y","volume":"257","author":"O Hornykiewicz","year":"2010","unstructured":"Hornykiewicz O. A brief history of levodopa. J Neurol. 2010;257(Suppl 2):S249\u201352.","journal-title":"J Neurol"},{"issue":"3","key":"2600_CR6","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448\u201358.","journal-title":"Mov Disord"},{"issue":"6","key":"2600_CR7","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548\u201360.","journal-title":"JAMA"},{"key":"2600_CR8","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.parkreldis.2015.11.007","volume":"22","author":"A Bjornestad","year":"2016","unstructured":"Bjornestad A, Forsaa EB, Pedersen KF, Tysnes OB, Larsen JP, Alves G. Risk and course of motor complications in a population-based incident Parkinson\u2019s disease cohort. Parkinsonism Relat Disord. 2016;22:48\u201353.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"2600_CR9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1055\/s-0037-1602423","volume":"37","author":"ME Freitas","year":"2017","unstructured":"Freitas ME, Hess CW, Fox SH. Motor complications of dopaminergic medications in Parkinson\u2019s disease. Semin Neurol. 2017;37(2):147\u201357.","journal-title":"Semin Neurol"},{"issue":"8","key":"2600_CR10","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/mds.25364","volume":"28","author":"CW Olanow","year":"2013","unstructured":"Olanow CW, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, et al. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson\u2019s disease. Mov Disord. 2013;28(8):1064\u201371.","journal-title":"Mov Disord"},{"issue":"Pt 10","key":"2600_CR11","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1093\/brain\/awu195","volume":"137","author":"R Cilia","year":"2014","unstructured":"Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, et al. The modern pre-levodopa era of Parkinson\u2019s disease: insights into motor complications from sub-Saharan Africa. Brain. 2014;137(Pt 10):2731\u201342.","journal-title":"Brain"},{"issue":"5","key":"2600_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S1474-4422(20)30036-3","volume":"19","author":"RMA de Bie","year":"2020","unstructured":"de Bie RMA, Clarke CE, Espay AJ, Fox SH, Lang AE. Initiation of pharmacological therapy in Parkinson\u2019s disease: when, why, and how. Lancet Neurol. 2020;19(5):452\u201361.","journal-title":"Lancet Neurol"},{"issue":"10","key":"2600_CR13","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/S1474-4422(09)70225-X","volume":"8","author":"A Antonini","year":"2009","unstructured":"Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkinson\u2019s disease. Lancet Neurol. 2009;8(10):929\u201337.","journal-title":"Lancet Neurol"},{"issue":"9949","key":"2600_CR14","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","volume":"384","author":"R Gray","year":"2014","unstructured":"PD MED Collaborative Group, Gray R, Ives N, Rick C, Patel S, Gray A, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\u2019s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014;384(9949):1196\u2013205.","journal-title":"Lancet"},{"issue":"16","key":"2600_CR15","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1503\/cmaj.151179","volume":"188","author":"P Rizek","year":"2016","unstructured":"Rizek P, Kumar N, Jog MS. An update on the diagnosis and treatment of Parkinson disease. CMAJ. 2016;188(16):1157\u201365.","journal-title":"CMAJ"},{"issue":"6","key":"2600_CR16","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/mds.27340","volume":"33","author":"A Antonini","year":"2018","unstructured":"Antonini A, Moro E, Godeiro C, Reichmann H. Medical and surgical management of advanced Parkinson\u2019s disease. Mov Disord. 2018;33(6):900\u20138.","journal-title":"Mov Disord"},{"issue":"5","key":"2600_CR17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.pneurobio.2007.05.001","volume":"83","author":"SN Schiffmann","year":"2007","unstructured":"Schiffmann SN, Fisone G, Moresco R, Cunha RA, Ferr\u00e9 S. Adenosine A2A receptors and basal ganglia physiology. Prog Neurobiol. 2007;83(5):277\u201392.","journal-title":"Prog Neurobiol"},{"issue":"6","key":"2600_CR18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.parkreldis.2008.12.006","volume":"15","author":"P Jenner","year":"2009","unstructured":"Jenner P, Mori A, Hauser R, Morelli M, Fredholm BB, Chen JF. Adenosine, adenosine A2A antagonists, and Parkinson\u2019s disease. Parkinsonism Relat Disord. 2009;15(6):406\u201313.","journal-title":"Parkinsonism Relat Disord"},{"key":"2600_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/978-3-319-20273-0_13","volume-title":"The adenosinergic system: a non-dopaminergic target in Parkinson\u2019s disease (Current Topics in Neurotoxicity, volume 10)","author":"A Mori","year":"2015","unstructured":"Mori A, LeWitt P, Jenner P. The story of istradefylline \u2013 The first approved A2A antagonist for the treatment of Parkinson\u2019s disease. In: Morelli M, Simola N, Wardas J, editors. The adenosinergic system: a non-dopaminergic target in Parkinson\u2019s disease (Current Topics in Neurotoxicity, volume 10). Switzerland: Springer International Publishing; 2015. p. 273\u201389."},{"issue":"23","key":"2600_CR20","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1212\/01.wnl.0000313834.22171.17","volume":"70","author":"M Stacy","year":"2008","unstructured":"Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008;70(23):2233\u201340.","journal-title":"Neurology"},{"issue":"15","key":"2600_CR21","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1002\/mds.22095","volume":"23","author":"RA Hauser","year":"2008","unstructured":"Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, et al. Study of istradefylline in patients with Parkinson\u2019s disease on levodopa with motor fluctuations. Mov Disord. 2008;23(15):2177\u201385.","journal-title":"Mov Disord"},{"issue":"3","key":"2600_CR22","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ana.21315","volume":"63","author":"PA LeWitt","year":"2008","unstructured":"LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces \u201coff\u201d time in Parkinson\u2019s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63(3):295\u2013302.","journal-title":"Ann Neurol"},{"issue":"10","key":"2600_CR23","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/mds.23107","volume":"25","author":"Y Mizuno","year":"2010","unstructured":"Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M. Japanese Istradefylline Study Group. Clinical efficacy of istradefylline (KW-6002) in Parkinson\u2019s disease: a randomized, controlled study. Mov Disord. 2010;25(10):1437\u201343.","journal-title":"Mov Disord"},{"issue":"8","key":"2600_CR24","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/mds.25418","volume":"28","author":"Y Mizuno","year":"2013","unstructured":"Mizuno Y, Kondo T. Japanese Istradefylline Study Group. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson\u2019s disease. Mov Disord. 2013;28(8):1138\u201341.","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"2600_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jns.2012.08.030","volume":"324","author":"W Chen","year":"2013","unstructured":"Chen W, Wang H, Wei H, Gu S, Wei H. Istradefylline, an adenosine A2A receptor antagonist, for patients with Parkinson\u2019s disease: a meta-analysis. J Neurol Sci. 2013;324(1\u20132):21\u20138.","journal-title":"J Neurol Sci"},{"issue":"1","key":"2600_CR26","doi-asserted-by":"publisher","first-page":"18018","DOI":"10.1038\/s41598-017-18339-1","volume":"7","author":"W Sako","year":"2017","unstructured":"Sako W, Murakami N, Motohama K, Izumi Y, Kaji R. The effect of istradefylline for Parkinson\u2019s disease: a meta-analysis. Sci Rep. 2017;7(1):18018.","journal-title":"Sci Rep"},{"issue":"1","key":"2600_CR27","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s12013-014-0162-7","volume":"71","author":"Y Tao","year":"2015","unstructured":"Tao Y, Liang G. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson\u2019s disease: a meta-analysis of randomized controlled trials. Cell Biochem Biophys. 2015;71(1):57\u201362.","journal-title":"Cell Biochem Biophys"},{"issue":"15","key":"2600_CR28","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1080\/14656566.2018.1518433","volume":"19","author":"M Takahashi","year":"2018","unstructured":"Takahashi M, Fujita M, Asai N, Saki M, Mori A. Safety and effectiveness of istradefylline in patients with Parkinson\u2019s disease: interim analysis of a post-marketing surveillance study in Japan. Expert Opin Pharmacother. 2018;19(15):1635\u201342.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"2600_CR29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1358\/dot.2020.56.2.3098156","volume":"56","author":"DM Paton","year":"2020","unstructured":"Paton DM. Istradefylline: adenosine A2A receptor antagonist to reduce \u201cOFF\u201d time in Parkinson\u2019s disease. Drugs Today (Barc). 2020;56(2):125\u201334.","journal-title":"Drugs Today (Barc)"},{"issue":"3","key":"2600_CR30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1212\/01.WNL.0000073136.00548.D4","volume":"61","author":"W Bara-Jimenez","year":"2003","unstructured":"Bara-Jimenez W, Sherzai A, Dimitrova T, Favit A, Bibbiani F, Gillespie M, et al. Adenosine A2A receptor antagonist treatment of Parkinson\u2019s disease. Neurology. 2003;61(3):293\u20136.","journal-title":"Neurology"},{"issue":"4","key":"2600_CR31","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1254\/jphs.13250FP","volume":"124","author":"S Uchida","year":"2014","unstructured":"Uchida S, Tashiro T, Kawai-Uchida M, Mori A, Jenner P, Kanda T. The adenosine A2A-receptor antagonist istradefylline enhances the motor response of L-DOPA without worsening dyskinesia in MPTP-treated common marmosets. J Pharmacol Sci. 2014;124(4):480\u20135.","journal-title":"J Pharmacol Sci"},{"issue":"6","key":"2600_CR32","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/WNF.0000000000000249","volume":"40","author":"I Yabe","year":"2017","unstructured":"Yabe I, Kitagawa M, Takahashi I, Matsushima M, Sasaki H. The efficacy of istradefylline for treating mild wearing-off in Parkinson disease. Clin Neuropharmacol. 2017;40(6):261\u20133.","journal-title":"Clin Neuropharmacol"},{"key":"2600_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ejphar.2015.09.028","volume":"766","author":"S Uchida","year":"2015","unstructured":"Uchida S, Soshiroda K, Okita E, Kawai-Uchida M, Mori A, Jenner P, et al. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets. Eur J Pharmacol. 2015;766:25\u201330.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"2600_CR34","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30(12):1591\u2013601.","journal-title":"Mov Disord"},{"issue":"9","key":"2600_CR35","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/mds.20213","volume":"19","author":"CG Goetz","year":"2004","unstructured":"Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020\u20138.","journal-title":"Mov Disord"},{"issue":"7","key":"2600_CR36","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/mds.22890","volume":"25","author":"RL Watts","year":"2010","unstructured":"Watts RL, Lyons KE, Pahwa R, Sethi K, Stern M, Hauser RA, et al. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson\u2019s disease. Mov Disord. 2010;25(7):858\u201366.","journal-title":"Mov Disord"},{"issue":"1","key":"2600_CR37","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4103\/aian.AIAN_460_18","volume":"23","author":"RT Athulya","year":"2020","unstructured":"Athulya RT, Jayakrishnan S, Iype T, Rajan R, Alapatt PJ. Predictors of levo-dopa induced dyskinesias in Parkinson\u2019s disease. Ann Indian Acad Neurol. 2020;23(1):44\u20137.","journal-title":"Ann Indian Acad Neurol"},{"issue":"1","key":"2600_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10072-019-04043-7","volume":"41","author":"G Liu","year":"2020","unstructured":"Liu G, Chen H, Su D, Wang D, Zhang M, Wang X, et al. Risk thresholds of levodopa dose for dyskinesia in Chinese patients with Parkinson\u2019s disease: a pilot study. Neurol Sci. 2020;41(1):111\u20138.","journal-title":"Neurol Sci"},{"key":"2600_CR39","doi-asserted-by":"publisher","first-page":"477","DOI":"10.3389\/fneur.2019.00477","volume":"10","author":"X Zhou","year":"2019","unstructured":"Zhou X, Guo J, Sun Q, Xu Q, Pan H, Yu R, et al. Factors associated with dyskinesia in Parkinson\u2019s disease in Mainland China. Front Neurol. 2019;10:477.","journal-title":"Front Neurol"},{"key":"2600_CR40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.parkreldis.2020.02.013","volume":"72","author":"R Bhidayasiri","year":"2020","unstructured":"Bhidayasiri R, Panyakaew P, Trenkwalder C, Jeon B, Hattori N, Jagota P, et al. Delivering patient-centered care in Parkinson\u2019s disease: challenges and consensus from an international panel. Parkinsonism Relat Disord. 2020;72:82\u20137.","journal-title":"Parkinsonism Relat Disord"},{"key":"2600_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fnagi.2020.00004","volume":"12","author":"A Iarkov","year":"2020","unstructured":"Iarkov A, Barreto GE, Grizzell JA, Echeverria V. Strategies for the treatment of Parkinson\u2019s disease: beyond dopamine. Front Aging Neurosci. 2020;12:4.","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"2600_CR42","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/S1474-4422(20)30065-X","volume":"19","author":"AHV Schapira","year":"2020","unstructured":"Schapira AHV. A pragmatic, personalised approach to treatment initiation in Parkinson\u2019s disease. Lancet Neurol. 2020;19(5):376\u20138.","journal-title":"Lancet Neurol"},{"issue":"2","key":"2600_CR43","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/mds.20279","volume":"20","author":"S Chapuis","year":"2005","unstructured":"Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson\u2019s disease on the quality of life. Mov Disord. 2005;20(2):224\u201330.","journal-title":"Mov Disord"},{"issue":"12","key":"2600_CR44","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/j.1468-1331.2005.01096.x","volume":"12","author":"M P\u00e9chevis","year":"2005","unstructured":"P\u00e9chevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-Voinet C, Berdeaux G, et al. Effects of dyskinesias in Parkinson\u2019s disease on quality of life and health-related costs: a prospective European study. Eur J Neurol. 2005;12(12):956\u201363.","journal-title":"Eur J Neurol"},{"issue":"10","key":"2600_CR45","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/mds.21475","volume":"22","author":"G Fabbrini","year":"2007","unstructured":"Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord. 2007;22(10):1379\u201389.","journal-title":"Mov Disord"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02600-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-02600-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-02600-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T10:00:46Z","timestamp":1700301646000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-02600-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2600"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-02600-w","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,3]]},"assertion":[{"value":"14 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complies with the Japan Clinical Trials Act and all relevant national and international guidance for the conduct of human trials, and with the Declaration of Helsinki. The study protocol (Version 4.1, 14 March 2019) and all other study documentation were reviewed and approved by the Juntendo University Certified Review Board (J18-006), approval number CRB3180012. All patients are providing or have provided written informed consent prior to participation. All patient data are anonymized; data obtained from the wearable device will not specify any personal information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study is funded by Kyowa Kirin Co., Ltd., Tokyo, Japan (commercial organization). The funding organization has implemented a peer review process of the study protocol.TH is an associate editor\/member of the editorial board for BMC Neurology and reports receiving grants and honoraria or consultation fees from Kyowa Kirin Co., Ltd. during the conduct of the study.OK reports grants and consultation fees from Kyowa Kirin Co., Ltd. during the conduct of the study.RS is an associate editor\/member of the editorial board for BMC Neurology and reports grants and consultation fees from Kyowa Kirin Co., Ltd. during the conduct of the study.AY reports grants from Kyowa Kirin Co., Ltd. during the conduct of the study; and reports grants from Eisai Co., Ltd. and Sumitomo Dainippon Pharma, outside the submitted work.KS is an editorial board member of BMC Neurology, and reports grants from Kyowa Kirin Co., Ltd. during the conduct of the study.NN reports grants from Kyowa Kirin Co., Ltd. during the conduct of the study.YM reports grants from Kyowa Kirin Co., Ltd. during the conduct of the study.KN reports grants from Kyowa Kirin Co., Ltd. during the conduct of the study.NYo reports grants from Kyowa Kirin Co., Ltd. during the conduct of the study.MS reports grants from Kyowa Kirin Co., Ltd. during the conduct of the study; and received a Takeda Japan Medical Affairs Funded Research Grant 2018, and grants from Kanae Foundation for the promotion of medical science, outside the submitted work.MM reports grants from Kyowa Kirin Co., Ltd. during the conduct of the study.HT reports grants and personal fees from Kyowa Kirin Co., Ltd. during the conduct of the study.KK reports grants and personal fees from Kyowa Kirin Co., Ltd. during the conduct of the study; and personal fees from Medtronic, Boston Scientific, Ono Pharmaceuticals Co., Ltd., Otsuka Pharmaceuticals Co., Ltd., AbbVie GK, Eisai Co., Ltd., Takeda Pharmaceuticals Co., Ltd., and Sumitomo Dainippon Pharma, and grants from Novartis AG, outside the submitted work.JT reports grants and non-financial support from Kyowa Kirin Co., Ltd. during the conduct of the study; and personal fees and non-financial support from Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., and FP Pharmaceutical Corporation, and non-financial support from Eisai Co., Ltd. and AbbVie GK outside the submitted work.SH reports grants from Kyowa Kirin Co., Ltd. during the conduct of the study; and grants from Eli Lilly Japan K.K., and grants and lecture fees from Nihon Medi-Physics Co., Ltd. outside the submitted work.HM reports grants from Kyowa Kirin Co., Ltd. during the conduct of the study.HJ reports grants from Kyowa Kirin Co., Ltd. during the conduct of the study.TU reports grants from Kyowa Kirin Co., Ltd. during the conduct of the study.HS reports grants and lecture fees from Kyowa Kirin Co., Ltd. during the conduct of the study.KO reports grants from Kyowa Kirin Co., Ltd. during the conduct of the study.JF reports grants from Kyowa Kirin Co., Ltd. during the conduct of the study.YT reports grants from Kyowa Kirin Co., Ltd. during the conduct of the study.KT reports grants from Kyowa Kirin Co., Ltd. during the conduct of the study.TY reports grants from Kyowa Kirin Co., Ltd. during the conduct of the study.NYa reports grants and consultant fees from Kyowa Kirin Co., Ltd. during the conduct of the study.HN reports grants and consultant fees from Kyowa Kirin Co., Ltd. during the conduct of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}